$IBIO I am more of an observer than contributor on st. However I was reviewing Tom's presentation at ubs conference. I have been thinking about it regularly since it was first broadcast. In the presentation at the 6 minute mark Tom said "in the field of cancer we can convey greater adcc , antibody dependent cellular citotoxicity, with our platform without encumbering intellectual property matters that are sometimes a challenge with the traditional bio process system." He went on to explain and said " so with our plant based systems we get some additional controls and we've upgraded all our capabilities in bio analytics to help enable comparability studies and other assays to be performed in the space." It seems to me with the ability apparently to produce product without running into "patent " (encumbering intellectual property) because of the system is beyond huge ..!as they can develop product and compare it to existing without running into intellectual property matters!! DISRUPTIVE
10
1
32